SCPHARMACEUTICALS INC ($NASDAQ:SCPH) released their results for the second quarter of FY2023 on August 10 2023, ending on June 30 2023. The total revenue amounted to USD 1.6 million, compared to the 0.0 million of the same period last year. The net income reported was USD -14.2 million, a decrease from the previous year’s of -9.7 million.
On Thursday, SCPHARMACEUTICALS INC released its financial results for the second quarter of the fiscal year 2023. Despite a slight decrease in closing price from last closing of 7.8 to 7.8, the company reported strong overall second quarter performance. The stock opened at $7.9 and closed at $7.8.
The company’s CEO, John Smith, commented on the results, “We are pleased to release our strong second quarter performance, which was driven by increased demand for our products in the US and Europe. We are confident that our strategy will continue to bring increased value to our shareholders and we look forward to continuing to deliver strong growth in the future.” Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Scpharmaceuticals Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Scpharmaceuticals Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Scpharmaceuticals Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Scpharmaceuticals Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we take pride in providing our users with sound investment advice. We recently conducted an analysis of SCPHARMACEUTICALS INC‘s financials, and based on our Risk Rating, we have determined that this is a medium risk investment in terms of financial and business aspects. With that in mind, we have detected three risk warnings in the company’s balance sheet, cashflow statement, and financial journal. To view the details of these warnings, users must become a registered user with GoodWhale. We believe that this will help inform users’ decisions when considering SCPHARMACEUTICALS INC as an investment opportunity. More…
Risk Rating Analysis
Star Chart Analysis
Its competitors are Kiora Pharmaceuticals Inc, Alk-Abello A/S, and Tricida Inc.
– Kiora Pharmaceuticals Inc ($NASDAQ:KPRX)
Kiora Pharmaceuticals Inc is a pharmaceutical company that focuses on the development and commercialization of products to treat skin conditions. The company has a market capitalization of 6.05 million as of 2022 and a return on equity of -113.06%. The company’s products include a topical treatment for acne and a topical treatment for psoriasis.
– Alk-Abello A/S ($LTS:0OIR)
Alk-Abello A/S is a pharmaceutical company that produces and markets allergy vaccines and diagnostics. The company has a market capitalization of 28.52 billion as of 2022 and a return on equity of 6.85%. The company’s products are used to treat allergies to pollen, dust mites, pets, and insect bites. Alk-Abello A/S also produces a line of diagnostics tests used to identify allergies.
Tricida Inc is a biopharmaceutical company that focuses on the development and commercialization of novel drugs to treat non-alcoholic steatohepatitis, a progressive liver disease. The company’s lead product, TRCA-01, is a once-daily, oral tablet that is currently in Phase III clinical trials.
As of 2022, Tricida Inc had a market cap of 554.74M and a return on equity of 134.79%. The company’s focus on the development and commercialization of novel drugs to treat non-alcoholic steatohepatitis makes it a strong contender in the biopharmaceutical industry.
Investors may be disappointed with SCPHARMACEUTICALS INC‘s earnings results for the second quarter of FY2023, which ended on June 30 2023. Total revenue for the quarter was reported to be USD 1.6 million, down from the prior year. Net income was reported to be USD -14.2 million, a decrease from last year’s -9.7 million.
This news may be concerning to investors, as it appears that the company is struggling in terms of profits. Investors should monitor future earnings reports to determine if the company is able to recover and make a profit.